It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT) . Shares have lost about 1.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Sarepta Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Q2 Earnings Beat, Sales Mis ...

After touching a nearly four-year high of $173.25 on June 21, shares of biotech firm Sarepta Therapeutics Inc (NASDAQ:SRPT) steadily worked lower on the charts, touching a more than two-month low of $123.50 on Aug. 9. It's not all bad, however, as SRPT posted gains in five its last six sessions, putting its year-to-date lead at 39.3%. What's more, a historically bullish signal is flashing on the charts. According to data from Schaeffer's Senior Quantitative Analyst Rocky White, Sarepta Therapeutics stock is ...

Sarepta Therapeutics (SRPT) staged quite a slide after its June 21 three-year high of $173.25, closing six of the last seven weeks lower. The shares are in positive territory so far this week, however, as the stock extends a bounce off the $125 level. Plus, a historically bullish signal could provide support on the charts, adding to the stock's 36% year-to-date lead. Sarepta Therapeutics stock's pullback has it within one standard deviation of its 126-day moving average. According to Schaeffer's Senior Quan ...

Both of these biotechs are highly innovative companies. We are still in a bull market, but the biotech industry, as measured by the SPDR S&P Biotech ETF (an industry benchmark), hasn't been keeping up with broader equities this year. That's no reason to avoid biotech stocks -- after all, some are doing just fine. That's the case with Vertex Pharmaceuticals (VRTX -0.41%) and Sarepta Therapeutics (SRPT 0.87%). Although these drugmakers continue to perform well, both look to have plenty of upside. Let's find o ...

A downtrend has been apparent in Sarepta Therapeutics (SRPT) lately with too much selling pressure. The stock has declined 10.3% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicat ...

Sarepta Therapeutics, Inc. (SRPT) posted earnings of 7 cents per share in second-quarter 2024, beating the Zacks Consensus Estimate of breakeven earnings. In the year-ago period, the company posted a loss of 27 cents. The loss included depreciation and amortization expenses and stock-based compensation expenses. Adjusted earnings per share in the quarter stood at 44 cents against the year-ago period's adjusted loss of $1.01 per share. Sarepta recorded total revenues of $362.9 million, up 39% year over year. ...

For the quarter ended June 2024, Sarepta Therapeutics (SRPT) reported revenue of $362.93 million, up 38.9% over the same period last year. EPS came in at $0.07, compared to -$0.27 in the year-ago quarter. ...

Financial Data and Key Metrics Changes - For Q2 2024, the company recorded total revenues of $362.9 million, an increase of $101.7 million compared to $261.2 million in Q2 2023 [39] - Net product revenue for ELEVIDYS was $121.7 million, while the PMO franchise generated approximately $238.8 million, showing modest growth [40][41] - The company reported a GAAP net income of $6.5 million for Q2 2024, compared to a net loss of $23.9 million in Q2 2023 [41] Business Line Data and Key Metrics Changes - The Duchenne franchise generated net product revenues of approximately $361 million in Q2 2024, a 51% increase year-over-year [7] - ELEVIDYS achieved $121.7 million in net product revenue, while the PMO franchise saw revenues of roughly $239 million, indicating slight growth [10][11] - Individual net product sales included $129.8 million for EXONDYS 51, $77.4 million for AMONDYS 45, and $31.6 million for VYONDYS 53 [40] Market Data and Key Metrics Changes - The company anticipates net product revenue for 2025 to be between $2.9 billion and $3.1 billion, indicating strong market potential [9][17] - The company is experiencing robust demand from the Duchenne patient population, with significant interest in ELEVIDYS following its label expansion [12][13] Company Strategy and Development Direction - The company aims to treat the prevalent Duchenne population throughout the decade, transitioning to the incident population in 2030-2031 [9][53] - The focus remains on expanding access to ELEVIDYS and ensuring patient safety while navigating the complexities of gene therapy launches [19][20] - The company is committed to advancing its pipeline, including therapies for limb-girdle muscular dystrophy and other rare diseases [28][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the launch of ELEVIDYS, noting that the early demand signals are positive and that the company is well-prepared to meet patient needs [8][12] - The company expects moderate revenue growth in Q3 2024, with strong growth anticipated in Q4 2024 and beyond [8][17] - Management highlighted the importance of patient safety and education in the successful integration of new therapies into treatment regimens [19][20] Other Important Information - The company achieved cash flow positivity for the first time in its history and expects to maintain this status moving forward [35] - A termination of a development and supply agreement related to an adherent manufacturing process is expected to incur additional R&D expenses of approximately $55 million to $65 million [37][38] Q&A Session Summary Question: What is the actual bottleneck in the patient journey from prescription to drug administration? - Management clarified that there is no fundamental bottleneck, and the typical process from start form to infusion takes about three to five months, which is standard for such therapies [44][45][49] Question: How should the market think about the growth trajectory and peak sales for the upcoming years? - Management indicated that peak year sales will occur significantly in the back half of this decade, with a focus on treating the prevalent population throughout the decade [52][53] Question: What are the early launch data supporting the revenue guidance for 2025? - Management expressed confidence based on extensive experience with previous launches and current demand indicators, aligning with external market expectations [56][58]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol Name of exchange on which registered Common Stock, $0.0001 par value per share SRPT The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...

The mean estimate comprises 17 short-term price targets with a standard deviation of $22. While the lowest estimate of $165 indicates a 14.8% increase from the current price level, the most optimistic analyst expects the stock to surge 63.4% to reach $235. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. Sarepta Therapeutics (SRPT) closed the last trading session at ...